A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Launched by ACCUTAR BIOTECHNOLOGY INC · Mar 10, 2023
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new drug called AC676 to see how well it works for patients with certain types of blood cancers, specifically those who have not responded to previous treatments. The main goals are to find out the safest dose of AC676, understand its safety and how the body processes it, and see how effective it is in treating these cancers. The trial is currently looking for adult participants aged 18 and older who have been diagnosed with specific types of relapsed or refractory B-cell malignancies and have already received at least two prior treatments.
If you join this study, you will be monitored closely for any side effects and how well the drug is working. It’s important to note that there are some requirements to participate, such as not having received certain treatments recently or having specific medical conditions. This study aims to provide more options for patients with limited treatment choices, helping to improve care for those fighting these challenging diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult male and female patients, at least 18 years-of-age at the time of signature of the informed consent form (ICF).
- • 2. Patients with histologically confirmed relapsed/refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM).
- • 3. Must have received at least 2 prior systemic therapies or have no other therapies to provide significant clinical benefit in the opinion of the Investigator or who are not amenable (intolerability, patient choice) to standard therapies.
- Exclusion Criteria:
- Patients who meet any of the following criteria will be excluded from study entry:
- 1. Treatment with any of the following:
- • Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days).
- • Systemic chemotherapy within 14 days.
- • Radiation therapy within 14 days
- • Biologics (Antibodies) treatment within 28 days,
- • Radioimmunoconjugates or toxin conjugates within 12 weeks.
- • Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed.
- • Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD.
- • 2. History of central nervous system lymphoma/leukemia in remission for less than 2 years.
- • 3. Medical history of active bleeding within 2 months prior to study entry, or susceptible to bleeding by the judgement of investigator.
About Accutar Biotechnology Inc
Accutar Biotechnology Inc. is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for the treatment of serious diseases. With a strong focus on precision medicine, Accutar leverages cutting-edge technologies and a robust pipeline of drug candidates to address unmet medical needs in oncology and other critical therapeutic areas. The company emphasizes a collaborative approach, partnering with leading research institutions and industry experts to accelerate the development of transformative treatments. Committed to scientific excellence and patient-centric solutions, Accutar Biotechnology Inc. strives to enhance the quality of life for patients worldwide through its groundbreaking research and development initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Dallas, Texas, United States
Portland, Oregon, United States
Denver, Colorado, United States
Sarasota, Florida, United States
Nashville, Tennessee, United States
Columbus, Ohio, United States
Nashville, Tennessee, United States
Sarasota, Florida, United States
Denver, Colorado, United States
Nashville, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials